BPG is committed to discovery and dissemination of knowledge
Articles in Press
4/1/2024 8:35:00 AM | Browse: 37 | Download: 0
Publication Name World Journal of Gastrointestinal Oncology
Manuscript ID 90319
Country China
Category Medicine, Research & Experimental
Manuscript Type Basic Study
Article Title Epigenetic silencing schlafen-11 sensitizes esophageal cancer to ATM inhibitor
Manuscript Source Invited Manuscript
All Author List Jing Zhou, Mei-Ying Zhang, Ai-Ai Gao, Cheng Zhu, Tao He, James G Herman and Ming-Zhou Guo
Funding Agency and Grant Number
Funding Agency Grant Number
National Key Research and Development Program of China 2018YFA0208902
National Science Foundation of China U160428,182272632,81672318
Beijing Science Foundation of China 7171008
Youth Innovation Science Foundation of Chinese PLA general hospital 22QNCZ027
Corresponding Author Ming-Zhou Guo, MD, PhD, Professor, Department of Gastroenterology and Hepatology, The First Medical Center, Chinese PLA General Hospital, No. 28 Fuxing Road, Beijing 100853, China. guomingzhou@301hospital.org
Key Words Schlafen-11; Esophageal squamous cell carcinoma; DNA methylation; Synthetic lethality; AZD0156
Core Tip Targeting DNA damage repair (DDR) is a novel strategy for cancer therapy. Epigenetic-based synthetic lethality studies have been conducted recently. Schlafen-11 (SLFN11) has been reported to sensitize cancer cells by involving DDR. However, the detailed regulatory network in DDR remains controversial. This study explored the mechanism of SLFN11 in DDR, and further investigated the synthetic lethal efficiency of epigenetic silencing SLFN11 and ATM inhibitor. The results demonstrated that SLFN11 activated non-homologous end-joining and ATR/CHK1, while inhibiting the ATM/CHK2 signaling pathway. Epigenetic silencing SLFN11 sensitized esophageal cancer cells to ATM inhibitor both in vitro and in vivo.
Citation Zhou J, Zhang MY, Gao AA, Zhu C, He T, Herman JG, Guo MZ. Epigenetic silencing Schlafen-11 sensitizes esophageal cancer to ATM inhibitor. World J Gastrointest Oncol 2024; In press
Received
2023-11-30 03:32
Peer-Review Started
2023-11-30 03:32
To Make the First Decision
Return for Revision
2024-02-20 01:53
Revised
2024-02-26 15:07
Second Decision
2024-04-01 06:41
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2024-04-01 08:35
Articles in Press
2024-04-01 08:35
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
ISSN 1948-5204 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com